Table 4.

Pooled effects obtained in meta-analysis models for delta lesion score.

			CI 95%
Challenge	Treatment	Pooled effects (%)	Lower	Upper	I2 and P-value heterogeneity
E. acervulina	Overall	−117.83	−117.89	−177.77	100%, P < 0.001
	Lasalocid	−55.89	−85.44	−26.34	100%, P < 0.001
	Maduramycin	−58.48	−147.40	30.43	100%, P < 0.001
	Decoquinate	−503.27	−1252.84	246.30	100%, P < 0.001
	Nicarbazin+semduramicin	−46.34	−105.78	13.11	100%, P < 0.001
	Monensin	−20.59	−31.56	−9.63	100%, P < 0.001
	Salinomycin	−29.23	−46.42	−12.03	100%, P < 0.001
	Narasin+Nicarbazin	−18.70	−22.13	−15.26	100%, P < 0.001
	Nicarbazin	−33.63	−42.19	−25.08	100%, P < 0.001
E. maxima	Overall	−62.91	−144.41	18.59	100%, P < 0.001
	Lasalocid	−71.34	−78.39	−64.29	100%, P < 0.001
	Maduramycin	−15.20	−21.04	−9.36	100%, P < 0.001
	Decoquinate	−294.16	−795.60	207.27	100%, P < 0.001
	Nicarbazin+semduramicin	−15.01	−32.26	2.24	100%, P < 0.001
	Monensin	−38.48	−106.79	29.82	100%, P < 0.001
	Salinomycin	−17.28	−30.29	−4.27	100%, P < 0.001
	Narasin+Nicarbazin	−33.86	−80.34	12.62	100%, P < 0.001
	Nicarbazin	−17.96	−24.98	−10.94	100%, P < 0.001

CI: Confidence interval; I2: I-square test percentual and P-value of this. I-square is a heterogeneity test that evaluates if the differences between measures are random or more than expected. When heterogeneity is significant (I-square > 70–80% and/or P < 0.05), random effect models were used to calculate pooled effect. When not significant, fixed effect models were used. This procedure is necessary not to validate the results obtained, but to validate methods used to combine them. Significant or not significant differences between pooled effects of each compound can be evaluated by comparing confidence intervals and their intersections. Significant differences are when there is no intersections between CI.